Ipratropium bromide and noninvasive ventilation for treating COPD

Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition resulting from damage caused by harmful chemicals. These chemicals trigger a series of inflammatory responses that not only harm lung structure but also increase mucus production in the airways. COPD is characterized as a partially reversible condition with restricted airflow, leading to permanent damage in the respiratory system and lungs, shortness of breath, chronic coughing, and a gradual decline in lung function. This can ultimately result in reduced quality of life and, in severe cases, death. Acute respiratory failure due to high carbon dioxide levels is a common complication of COPD, associated with an increased need for respiratory support and a higher mortality risk; thus, non-invasive ventilation is recommended as the gold standard treatment.

Non-invasive ventilation can temporarily reverse or slow disease progression by providing ventilation support and avoiding the need for tracheal intubation. This method allows individuals to enhance airflow and gas exchange while reducing the effort needed to breathe, thereby improving lung mechanics. For patients, it helps clear mucus from the airways, enhances breathing during sleep, and may alleviate respiratory muscle fatigue. Non-invasive ventilation is widely used in managing acute respiratory failure from various causes, although some patients may not tolerate it well. Ipratropium bromide is an anticholinergic medication that can cause bronchiectasis by inhibiting the bronchodilation effects of cholinergic activity. One study indicated that treatment with ipratropium bromide can improve blood oxygen saturation and sleep quality in patients with moderate to severe COPD. This research investigated the effects of combining ipratropium bromide with non-invasive ventilation in patients suffering from both COPD and respiratory failure.

Method

This study enrolled 110 patients with both COPD and respiratory failure who were admitted to the hospital between April 2018 and August 2019. Among them, 52 patients received treatment with a non-invasive ventilator and were designated as Group A, while the remaining patients were treated with a combination of ipratropium bromide and non-invasive ventilation, forming Group B. The two groups were compared in terms of blood gas parameters, pulmonary function, treatment effectiveness, and adverse reactions.

Results

Following treatment, Group B exhibited superior blood gas parameters and pulmonary function compared to Group A (both P < 0.05). Additionally, Group B had significantly lower levels of inflammatory markers than Group A (P < 0.05). Furthermore, Group B demonstrated better treatment efficacy and quality of life, along with fewer adverse reactions compared to Group A (all P < 0.05).

Conclusion

In this study, Group B showed better levels of inflammatory factors, pulmonary function, and blood gas parameters compared to Group A. We hypothesize that the improved pulmonary function in Group B may be attributed to ipratropium bromide's ability to lower inflammatory factor levels, leading to bronchodilation and reduced mucus secretion. Additionally, Group B had a lower Borg score post-treatment, indicating that patients receiving ipratropium bromide experienced milder dyspnea and better treatment outcomes. One study has suggested that anticholinergic medications for COPD can alleviate dyspnea, slow disease progression, and enhance exercise tolerance, sleep quality, and overall quality of life. Another study supports the effectiveness and safety of inhaled ipratropium bromide for long-term COPD management. Moreover, research has indicated that incorporating ipratropium into standard COPD treatment can reduce emergency room treatment times. These findings collectively suggest that ipratropium bromide is effective for COPD.

Nebulized drug treatments are non-invasive and can effectively address respiratory diseases. We also noted fewer adverse reactions in patients receiving ipratropium bromide; similar studies have reported that the adverse effects of ipratropium are rare and typically mild. This may be because nebulized medications can more easily reach the alveolar regions of the lungs, improving gas exchange and tissue function with reduced invasiveness, resulting in fewer adverse reactions. Furthermore, the quality of life in Group B was higher, with another study showing that patients treated with ipratropium bromide scored better on quality of life assessments related to dyspnea, fatigue, emotional function, and overall well-being.

In summary, combining ipratropium bromide with non-invasive ventilation significantly reduces circulatory inflammation and enhances pulmonary function and blood gas levels, leading to improved treatment efficacy. Some studies suggest that the positive effects of bronchodilators on COPD patients during non-invasive ventilation may stem from the inhalation process, where equipment design affects drug particle distribution, decreasing particle size in the respiratory tract, lowering respiratory rate, and increasing tidal volume, thus enhancing drug delivery and bioavailability.

Reference

1. Hansel NN, McCormack MC, Kim V. The effects of air pollution and temperature on COPDCOPD.2016;13:372-379

2. Chong l, Leung B, Poole P, Phosphodiesterase 4 inhibitors for chronic obstructive pulmonarydisease.Cochrane Database Syst Rev. 2017;9:CD002309. 3. Barrett NA, Kostakou E, Hart N, Douiri A, Camporota L. Extracorporeal carbon dioxideremoval for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: studyprotocol for a randomised controlled trial. Trials.2019;20:465.

4. Herath Sc, Normansell R, Maisey S, Poole P Prophylactic antibiotic therapy for chronicobstructive pulmonary disease (COPD) Cochrane Database Syst Rev, 2018;10:cD009764.

5. Sun j, Li Y, Ling B, Zhu Q, Hu Y, Tan D, Geng P, Xu j. High flow nasal cannula oxygen therapyversus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. Int ] chron ObstructPulmon Dis. 2019;14:1229-1237.

6. Moran F, Bradley jM, Piper A]. Non-invasive ventilation for cystic fibrosis. Cochrane DatabaseSyst Rev 2017;2:cD002769.

7. Rochwerg B, Bro chard L, Elliott MW, Hess D, Hill NS, Nava S Paolo Navalesi Members of TheSteering Committee, Antonelli M, Brozek ], Conti G, Ferrer M, Guntupalli K, jaber S, Keenan SMancebo , Mehta s Suhail Raoof Members Of The Task Force. Official ERs/ATs clinical practiceguidelines: noninvasive ventilation for acute respiratory failure. Eur Respir ]. 2017;50:1602426

8. Nomura 0, Morikawa Y, Hagiwara Y, lhara T, Inoue N, Sakakibara H, Akasawa A. Ipratropiumbromide for acute asthma in children: a retrospective trial. Arerugi.

9. MacGregor TR, ZuWallack R, Rubano V, Castles MA, Dewberry H, Ghafouri M, Wood ccEfficiency of ipratropium bromide and albuterol deposition in the lung delivered via a soft mistinhaler or chlorofluorocarbon metered-dose inhaler, Clin Transl Sci. 2016;9:105-113.

10. Martin Rj, Bartelson BL, Smith P, Hudgel Dw, Lewis D, Pohl G, Koker P, Souhrada jF. Effect ofipratropium bromide treatment on oxygen saturation and sleep quality in COPD. chest.1999:115:1338-1345.